دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Spironolactone in dermatology
Diana Alejandra Aguilar Medina, Jorge CazarÃn, Mario Magaña
doi : 10.1111/dth.15321
Spironolactone is a drug, similar in structure to aldosterone and acts as an aldosterone receptor antagonist with an anti-androgenic effect. This drug has proven to be useful in several dermatological entities, however its use has not been well explored. Its use in diseases such as acne has opened the door to the possibility of new therapies depending on the clinical manifestations of the patients, as well as its possible to use it as a first line treatment. Other diseases associated with the use of spironolactone where its effects have been shown to be useful are hidradenitis suppurativa, hirsutism, and female pattern androgenetic alopecia. In this review, we discuss the use of spironolactone in different skin diseases that are common in our environment, dosage according to different studies, treatment recommendations and adverse effects; all of the above mentioned in order to use this drug in a daily clinical practice.
Cutaneous adverse reactions of COVID-19 vaccines: A systematic review
Kowsar Qaderi, Mohammad Hossein Golezar, Abbas Mardani, Manthar Ali Mallah, Bagher Moradi, Hossein Kavoussi, Ahmadreza Shamsabadi, Samira Golezar
doi : 10.1111/dth.15391
Numerous vaccines are under clinical development and implementation for the prevention of severe course and lethal outcomes of coronavirus disease 2019 (COVID-19). This systematic review aims to summarize and integrated the findings of studies regarding cutaneous side effects of COVID-19 vaccines. This systematic review conducted by searching the scientific databases of PubMed, Scopus, Science direct, and Web of knowledge from the beginning of the COVID-19 to May 10, 2021. Articles were reviewed and analyzed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist. Seventeen studies on cutaneous side effects of COVID-19 vaccines were included after the screening of search results based on to the eligibility criteria. The results showed that the most common injection site reactions and delayed large local reactions, arising from all vaccine types, were redness/erythema (39%), followed by: itchiness (28%), urticarial rash (17%) on the neck, upper limbs, and trunk, morbilliform eruptions (6.5%), Pityriasis rosea (3%), swelling, and burning, and so forth. Most cutaneous reactions occurred in women (84%), and middle-aged people, after the first dose of vaccine, with the onset ranged from 1 to 21 days after vaccination. In addition, cutaneous reactions were generally self-limiting, and needed little or no therapeutic intervention, that were not regarded as a barrier to injecting a second dose. In conclusion, severe cutaneous side effects are very rare and approved vaccines have satisfactory safety profiles. Therefore, mild or moderate cutaneous reactions should not discourage people from vaccination. In certain groups such as patients with allergies and a history of local injection reactions, pre-vaccination counseling and assurance, also use of appropriate medications may be helpful. However, more studies are needed to investigate the side effect profile of all COVID-19 vaccines.
A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors
Rachel Bierbrier, Megan Lam, Kevin Pehr
doi : 10.1111/dth.15412
Epidermal growth factor receptor inhibitors (EGFRi) are now standard of care in patients with EGFR mutations in non-small cell lung cancer (NSCLC) and are increasingly being used in other EGFR mutated cancers, including gastrointestinal, and head and neck. However, EGFRi are well known to cause acneiform eruptions, which are shown to positively correlate with tumor response to treatment, but may be severe enough to cause interruption of their treatment. Although most guidelines call for the use of tetracyclines to treat these acneiform eruptions, there is mounting evidence for the use of systemic retinoids instead. The objective of this review is to summarize available data on the use of systemic retinoids for management of acneiform eruptions on EGFRi. This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE and EMBASE were searched from database inception until December 10th, 2021. All articles were screened and relevant data extracted independently in duplicate by two reviewers. In total, 16 case reports, case series and retrospective reviews were included. Forty-three patients were treated with retinoids for their acneiform eruption due to EGFRi. The majority (77%) noted moderate to significant improvement after treatment initiation with minimal adverse events (16%). The findings of this systematic review suggest that systemic retinoids are a safe and effective therapy for the management of acneiform eruptions induced by EGFRi.
Remarkable efficiency of surgical shave excision of keloids followed by intralesional injection of Bleomycin. A retrospective study of 314 cases
Olivier Vanhooteghem
doi : 10.1111/dth.15425
The aim of this study was to determine the efficiency of a keloid treatment consisting of intradermal surgical shave excision followed by intralesional injections of Bleomycin. A retrospective study performed in the Department of Dermatology, CHU UCL Namur Sainte Elisabeth Clinic, Belgium between 2018 and 2019, on 314 patients with keloids—average age: 32 years (range 19–62).
SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review
Zeinab Aryanian, Kamran Balighi, Parvaneh Hatami, Azadeh Goodarzi, Nessa Aghazadeh Mohandesi, Zeinab Mohseni Afshar
doi : 10.1111/dth.15430
SARS-CoV2 vaccines were approved without long-term monitoring due to emergent situations. This has raised some issues about timing and protocol of receiving vaccines in specific situations including patients with chronic inflammatory disorders such as psoriasis. Here, we present different aspects of SARS-CoV-2 infection and vaccination in psoriasis patients and aim to provide solutions to overcome the potential challenges. In brief, the benefits of vaccination outweigh the potential risk; vaccine-triggered de novo or flares of psoriasis is uncommon. As such, all psoriasis patients, especially those receiving systemic treatments including anti tumor necrosis factor agents, are strongly recommended to get SARS-CoV-2 vaccines.
Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab
Rohan R. Shah, Chinmoy Bhate, Amanda Hernandez, Chin Hung Ho
doi : 10.1111/dth.15432
The widespread use of PD-1 inhibitors to treat various solid tumors has brought certain challenges for the clinician, including immune-related adverse events (irAEs). Cutaneous toxicities are among the most observed irAEs. Bullous and lichenoid dermatoses following PD-1 inhibitor therapy have been described. Here we report a novel case of lichen planus pemphigoides, featuring characteristics of both bullous pemphigoid and lichen planus, in a patient treated with nivolumab for renal cell carcinoma. We subsequently review all three cutaneous conditions which may arise in the context of PD-1 inhibitor therapy.
Impact of extracorporeal photopheresis on blood and coagulation parameters
Thilo Gambichler, Maria Chatzipantazi, Rene Stranzenbach, Alicia Feldkamp, Laura Susok
doi : 10.1111/dth.15366
Extracorporeal photopheresis (ECP) is considered a safe treatment modality. We aimed to assess blood parameters including coagulation during ECP over time. We performed a long-term retrospective single-center chart review (laboratory parameters) of adult patients (n = 172) who had received ECP for any indication. We observed a significant decrease (p < 0.05) in erythrocytes, hemoglobin, and leukocytes compared to baseline levels after only one ECP procedure.
A randomized, double-blind, multi-center, placebo-controlled, Phase 2 clinical trial to evaluate the efficacy and safety of DWJ211 in the treatment of moderate to severe submental fat
Seung Hwan Paik, Joon Min Jung, Chang Jin Jung, Hee Joo Yang, Hyung Seok Son, Sun Hye Shin, Kwang Ho Yoo, Yang Won Lee, Beom Joon Kim, Chong Hyun Won
doi : 10.1111/dth.15373
Excessive accumulation of submental fat (SMF) causes a lower face cosmetic problem. A lipolytic injectable has recently been developed as a solution. The objective of this study is to investigate the effects and safety of DWJ211 (a newly developed lipolytic injectable) in the reduction of SMF and to identify the optimum dose. In this multi-center, double-blind, placebo-controlled study, subjects with moderate to severe SMF were randomized to injections of DWJ211 0.5%, DWJ211 1%, DWJ211 2% or placebo in the submental area, every 4 weeks, up to Week 12.
Pharmacoeconomic study of biologics for psoriasis treatment based on real-world drug survival
Atsuyuki Saisyo, Michiya Yamaguchi, Koichi Kashibe, Haku Ishida, Yasushi Hirano, Tomoyuki Oka, Miho Tamura, Miwako Takasago, Yutaka Uchida, Kyoji Kouda, Takashi Kitahara
doi : 10.1111/dth.15375
The efficacy of biologics in psoriasis treatment is clinically proven; however, biologics are expensive. In this study, we assessed the real-world cost-effectiveness of biologics for psoriasis treatment by evaluating the relationship between biologic drug survival (DS) and total medical-treatment costs from a pharmacoeconomic viewpoint. Furthermore, the effects of patient factors on cost-effectiveness were investigated.
Microneedling with topical vitamin C versus microneedling with topical insulin in the treatment of atrophic post-acne scars: A split-face study
Mohamed Ali Mahmoud Abbas, Emad Eldin Abd Elmoneim Elgamal, Mohamed Shokry Zaky, Mohamed L. Elsaie
doi : 10.1111/dth.15376
Post acne scars following sebaceous injury and abnormal wound healing during the course of acne is a prevalent and challenging to treat condition To evaluate microneedling by dermapen with topical vitamin C versus microneedling with topical insulin in treating atrophic post-acne scars.
Risankizumab shows high efficacy and maintenance in improvement of response until week 52
Luca Mastorino, Sara Susca, Matteo Megna, Niccolò Siliquini, Pietro Quaglino, Michela Ortoncelli, Gianluca Avallone, Marco Rubatto, Gabriella Fabbrocini, Paolo Dapavo, Simone Ribero
doi : 10.1111/dth.15378
Risankizumab has been recently approved for moderate-to-severe plaque psoriasis; however, real-life studies are scarce. Analysis of possible predictor factors of treatment response are limited to body mass index (BMI) and previous biologic experience. Our objectives were to evaluate the effectiveness and safety of Risankizumab and to investigate on possible predictor factors response.
Hemorrhagic dot score as a follow up marker in psoriasis on treatment: A prospective observational study
Sandeep Arora, Debatraya Paul, Shantanu Banerjee, Richa Kumar, Eeshaan Ranjan, Rajeshwari Dabas
doi : 10.1111/dth.15379
Context: Psoriasis assessment tools in use presently lack reproducibility and are cumbersome to use. An easily reproducible, objective tool with ability to maintain visual records for follow up is hence desirable. We conducted a study with the aim to assess dermoscopic changes in psoriasis while on treatment by recording the number of hemorrhagic dots (Hemorrhagic Dot Score-HDS) in a representative plaque and comparing it to the PASI score.
Intralesional bivalent human papilloma virus vaccine as a treatment for anogenital warts versus topical podophyllin resin 25%: A pilot study
Eman Nofal, Shimaa Emam, Fatma Aldesoky, Soheir Ghonemy, Ahmad Adelshafy
doi : 10.1111/dth.15384
A role of human papilloma virus (HPV) vaccines as a therapy for genital warts was suggested, nevertheless; it has not been established in clinical trials and has yet to be determined. The objective of this study is to evaluate a potential benefit of intralesional injection of bivalent HPV (Cervarix) vaccine as a treatment for anogenital warts versus topical podophyllin resin 25%. Forty-four patients with anogenital warts were included in the study, 22 patients received intralesional Cervarix every 2 weeks until clearance of lesions or for a maximum of five sessions.
The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study
Ying Li, Jiajing Lu, Rongfen Chen, Yu Wang, Yangfeng Ding, Shuang Xu, Ying Zou, Xuemei Yi, Yuling Shi
doi : 10.1111/dth.15385
Little real-work data regarding the efficacy and safety of dupilumab in the treatment of atopic dermatitis (AD) is available at present. To assess the efficacy and safety of dupilumab at 12 weeks in the treatment of AD in clinical routine clinical practice. A retrospective, single-centre study of adult patients with moderate to severe AD treated with dupilumab for 12 weeks in China.
Efficacy and safety of ebastine dose escalation in chronic urticaria: A prospective study
Tian Qian, Shifei Li, Qiquan Chen, Daojun Zhang, Zhiqiang Song, Fei Hao
doi : 10.1111/dth.15386
The second-generation antihistamines at licensed doses are first-line treatment in urticaria and up-dosing is recommended as second-line treatment. To assess the efficacy and safety of escalated doses of ebastine in patients with chronic urticaria (CU), we designed this study. Recruited patients with CU were treated with increasing doses of ebstine. Treatment started at the daily dose of 10Â mg.
A randomized, controlled, split-face study of botulinum toxin and broadband light for the treatment of erythematotelangiectatic rosacea
Yao Tong, Wangsha Luo, Yulian Gao, Lufeng Liu, Qiuyue Tang, Qingbiao Wa
doi : 10.1111/dth.15395
To study the efficacy and safety of botulinum toxin (BTX) combined with broadband light (BBL) in the treatment of rosacea-related erythema and flushing. A randomized, single-blind, split-face controlled study including 22 patients with erythemato telangiectatic rosacea were enrolled. Both cheeks were randomly divided into experimental group and control group.
Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients
Adi Nosrati, Tomer Mimouni, Emmilia Hodak, Michael Gdalevich, Meital Oren-Shabtai, Assi Levi, Daniel Mimouni, Yael A. Leshem
doi : 10.1111/dth.15397
Rituximab is the front-line therapy for pemphigus disease. Although very effective, relapse rates are high. We assessed factors associated with disease remission and early relapse following the first rituximab cycle. A single center, retrospective cohort study of patients with pemphigus treated with rituximab (1000 mg 0, 14 days) at the Autoimmune Bullous Disease Clinic of the Division of Dermatology in Rabin Medical Center, Israel, between January 1, 1995 and March 31, 2020. The cohort included 99 patients with a median follow-up of 37 months (range 12–155). After a single rituximab cycle, 74 patients (75%) achieved remission.
The application of electrolysis of depigmented hair using a trichiasis electrolyzer combined with single hair follicle transplantation for the treatment of vitiligo-associated leukotrichia
Yi Wu, Yeqin Dai, Tao Wang, Hong Jin, Jianzhong Peng, Ai'er Xu
doi : 10.1111/dth.15400
Leukotrichia is one of the difficulties of vitiligo treatment. Hair follicle transplantation is an efficient method to treat vitiligo-associated leukotrichia. A trichiasis electrolyzer, commonly used for treating trichiasis, can be used to damage and remove the depigmented hair follicles. To evaluate the efficacy of the electrolysis of depigmented hair using a trichiasis electrolyzer combined with single hair follicle transplantation for the treatment of vitiligo-associated leukotrichia.
A multi center real world observation to evaluate the efficacy of cryotherapy versus local hyperthermia for the treatment of plane warts
Sheng-Nan Zhao, Wei Huo, Qian An, Tian-Wen Gao, Zhi-Rong Yao, Jian-Zhong Zhang, Xue-Jun Zhang, Heng Gu, Ri-Na Wu, Hong-Guang Lu, Xiu-Ping Han, Fan-Qin Zeng, Rong-Zhen An, Lei Ma, Hong-Duo Chen, Rui-Qun Qi, Xing-Hua Gao
doi : 10.1111/dth.15403
Most plane warts are recalcitrant to treatment. Both cryotherapy and local hyperthermia have been applied to treat plane warts. However, no direct comparative study on their respective efficacy and safety has ever been performed. To assess the efficacy and safety of local hyperthermia at 43 ± 1°C versus liquid nitrogen cryotherapy for plane warts. Sequential patients with plane warts entered the study, either receiving cryotherapy or local hyperthermia therapy at the discretion of the patients and the recommendations of consultants. Cryotherapy with liquid nitrogen was delivered in two sessions 2 weeks apart, while local hyperthermia was delivered on three consecutive days, plus two similar treatments 10 ± 3 days later.
Hematoporphyrin monomethyl ether photodynamic therapy for the treatment of Sturge–Weber syndrome and large segmental facial port-wine stain
Xiaoxue Li, Ping Diao, Liang Liu, Hui Zhou, Yi Yang, Chenglong Han, Xian Jiang
doi : 10.1111/dth.15404
Hematoporphyrin monomethyl ether (HMME) is a newly authorized photosensitizer for the treatment of port-wine stain (PWS) in China. However, no research on its efficacy for treating PWS lesions of Sturge–Weber syndrome (SWS) has been made. To assess the efficacy and safety of HMME-photodynamic therapy (PDT) in the treatment of SWS and simple large segmental facial PWS.
An exploration of optimal time and safety of 595-nm pulsed dye laser for the treatment of early superficial infantile hemangioma
Hui-Yi He, Wei-Kang Shi, Ji-Cong Jiang, Yu Gao, Xi-Mao Xue
doi : 10.1111/dth.15406
Infantile hemangioma (IH) is the most common benign vascular tumor that occurs in infants and young children. Studies have shown laser therapy to reduce the proliferation of superficial IH and promote its regression, but the optimal timing for treatment has not been determined. Our study explores the timing and safety of 595-nm pulsed dye laser (PDL) treatment for early superficial IH. We retrospectively analyzed 180 cases of superficial IH treated with 595-nm PDL.
Impact on health-related quality of life and symptoms of anxiety and depression after 32 weeks of Dupilumab treatment for moderate-to-severe atopic dermatitis
Marco Miniotti, Giulia Lazzarin, Michela Ortoncelli, Luca Mastorino, Simone Ribero, Paolo Leombruni
doi : 10.1111/dth.15407
Dupilumab is the first biological agent approved for treatment of moderate-to-severe atopic dermatitis (AD). Evidence of Dupilumab effectiveness on psychological outcomes beyond 16 weeks of treatment from real-life settings is lacking. To evaluate the effectiveness of Dupilumab treatment up to 32 weeks, focusing health-related quality of life and psychological outcome of patients with moderate-to-severe AD. An observational prospective cohort study was conducted in a real-life setting at an Italian tertiary centre.
Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals—Prospective observational cohort study
Éva Anna Piros, Orsolya Cseprekál, Anna Görög, Bernadett Hidvégi, Márta Medvecz, Zsófia Szabó, Ferenc Olajos, Eszter Barabás, Noémi Galajda, Pál Miheller, Péter Holló
doi : 10.1111/dth.15408
It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)-based antisevere acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) vaccinations. To assess antibody formation and the incidence of side effects after anti-SARS-CoV-2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls. 102 moderate-to-severe psoriatic patients (56.2 [±13.5] years) and 55 age-matched healthy (56.4 ± 13.6 years) volunteers were included in our study.
Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center
Nisha V. Parmar, Mohamed Ahmed Abdula, Amani Al Falasi, C. Vijay Krishna
doi : 10.1111/dth.15415
Dupilumab is a monoclonal antibody against interleukins 4 and 13 currently FDA approved for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents and severe AD in children aged 6–11 years. It is reported to be safe with the most common side effects described from clinical trials being conjunctivitis, nasopharyngitis and injection site reactions.
COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients
Züleyha Özgen, Hasan Aksoy, Özlem Akın Çakıcı, Ayşe Esra Koku Aksu, Ozan Erdem, Asude Kara Polat, Mehmet Salih Gürel
doi : 10.1111/dth.15417
There are safety concerns in the treatment of pemphigus patients with immunosuppressants, particularly rituximab (RTX), in times of the COVID-19 pandemic. In the beginning, the reports were more pessimistic. However, few reports have recently pointed to manageable courses in this patient group. Therefore, we investigated the disease characteristics and demographic features of pemphigus patients in the period of the COVID-19 pandemic. We aimed to investigate the impact of immunosuppressants on the course of COVID-19 in pemphigus patients.
Treatment of early-stage mycosis fungoides with oral bexarotene and phototherapy: A systematic review and meta-analysis
Erica Ginsburg, Kerry Hennessy, Rahul Mhaskar, Lucia Seminario-Vidal
doi : 10.1111/dth.15418
Mycosis fungoides (MF) is a rare subtype of non-Hodgkin lymphoma, for which no standard treatment exists. The objective of this study is to provide evidence-based recommendations for adult patients with early-stage MF treated with oral bexarotene and phototherapy. A systematic review and meta-analysis was conducted utilizing studies identified via Embase, Pubmed, Web of Science, and the Cochrane Library from inception to April 2020 to evaluate the clinical efficacy and adverse events of oral bexarotene and phototherapy. Of 645 abstracts retrieved, 17 full-text articles with 143 subjects were included for analysis.
Comparative study of treatment methods for benign lichenoid keratosis of the face
Ji Ha Yoon, Eun Joo Baek, Eun Joo Park, Kwang Ho Kim
doi : 10.1111/dth.15419
Benign lichenoid keratosis is one of the most common skin lesions that develop on the faces of middle-aged women. This study aimed to find an effective treatment method for benign lichenoid keratosis. A total of 49 patients, who had a positive diagnosis during 2010–2018, were enrolled in the study. An Investigator's Global Assessment of the lesion was done using the 5-point visual analog scale to evaluate treatment efficacy. After excluding subjects who did not have a follow-up photograph, 38 subjects were given an Investigator's Global Assessment score. Combination therapy using laser and a topical agent was useful in the management of benign lichenoid keratosis on the face. Ablative laser was effective for immediate improvement of the lesion, whereas non-ablative laser was also useful and showed several benefits over ablative laser. Optimal treatment should be decided after considering the patient's preference, compliance with treatment regimen, and skin type.
Safety and efficacy of high-intensity focused ultrasound for treatment of periorbital, perioral, and neck wrinkles: Prospective open single-center single-arm confirmatory clinical trial
Hye Sung Han, Jae Wan Park, Soo Yeon Kim, Kwang Ho Yoo, Sun Young Choi, Beom Joon Kim
doi : 10.1111/dth.15420
Neonatal ischemic limb lesions: From etiology to topical nitroglycerine. A case series analysis
Raffaele Falsaperla, Manuela Lo Bianco, Andrea Giugno, Germana Lena, Laura Sciuto, Francesco Spata, Claudio Guarneri, Piero Pavone, Martino Ruggieri
doi : 10.1111/dth.15426
Therapeutic potential of second degree's skin burns by topical dressing of Teucrium ramosissimum that promotes re-epithelialization
Fatma Guesmi, Issam Saidi, Raoudha Abbassi, Mabrouka Saidani, Najla Hfaiedh, Ahmed Landoulsi
doi : 10.1111/dth.15428
Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome
Guldane Cengiz Seval, Ugur Sahin, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Pervin Topcuoglu, Bengu Nisa Akay, Hatice Erdi Sanlı, Gunhan Gurman, Selami Kocak Toprak, Muhit Ozcan
doi : 10.1111/dth.15447
Proactive therapy: New perspectives for long-term topical treatment of psoriasis
Anna Lis-Święty, Aleksandra Frątczak
doi : 10.1111/dth.15364
Oral cinnarizine for the treatment of COVID-19-associated chilblain-like lesions: An old drug for a new disease?
Carlo Mazzatenta, Vincenzo Piccolo, Giuseppe Argenziano, Andrea Bassi
doi : 10.1111/dth.15365
5-Fluorouracil 0.5%/salicylic acid 10% solution in the treatment of ano-genital warts
Giulia Ciccarese, Aurora Parodi, Francesco Drago
doi : 10.1111/dth.15370
Novel uses of laser therapy in Goltz syndrome
Nieves MartÃnez-Campayo, Isidro Rego-Campuzano, Jesús del Pozo, Sabela Paradela, Ã�ngel Fernandez-Flores, Eduardo Fonseca
doi : 10.1111/dth.15371
A practical guide to the safety of topical medications for the pediatric population
Manal Fawzy, Basma ElKholy
doi : 10.1111/dth.15377
Association between human leukocyte antigens and cutaneous adverse drug reactions to antiepileptics and antibiotics in the Iranian population
Hossein Mortazavi, Anahita Rostami, Alireza Firooz, Nafiseh Esmaili, Maryam Ghiasi, Vahideh Lajevardi, Ali Akbar Amirzargar, Iman Sheykhi, Ali Khamesipour, Marwa Akhdar
doi : 10.1111/dth.15393
Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation
Gulsen Akoglu
doi : 10.1111/dth.15396
Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients
Theodora Tsironi, Georgios Gaitanis, Charalambos Pappas, Vasileios Koutlas, Evangelia Dounousi, Ioannis D. Bassukas
doi : 10.1111/dth.15405
An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: Toxic epidermal necrolysis
Masoud Mardani, Sayna Mardani, Zahra Asadi Kani, Atousa Hakamifard
doi : 10.1111/dth.15416
Two clinical subtypes with different management of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: A single centre experience
Daniel Falkenhain-López, Alba Sánchez-Velázquez, Jon Fulgencio-Barbarin, Mario Puerta-Peña, Pablo Luis Ortiz-Romero, Concepción Postigo-Llorente, Raquel Rivera-DÃaz
doi : 10.1111/dth.15362
Erythroderma related with the first dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine in a patient with psoriasis
Oyku Durmus, Neslihan Akdogan, Omer Karadag, Ozay Gokoz
doi : 10.1111/dth.15363
Vasculitis in the setting of COVID-19: From the disease to the vaccine. Report of a case of cutaneous vasculitis after immunization
Paulo Ricardo Criado, Lucas Prezotto Giordani, Thais Akemi Yoshimoto, Ingrid Campos Vieira, Gilles Landman, Thais Prota Pincelli
doi : 10.1111/dth.15367
Psoriasis exacerbation after COVID-19 vaccination in high-risk group: How to manage it?
Mariam Kabbani, Maud Poskin, Farida Benhadou
doi : 10.1111/dth.15368
The case of granuloma annulare associated with SARS-CoV-2 infection
Selma Emre, Esranur Unal, Burak Celik, Nuran Sungu
doi : 10.1111/dth.15369
A new combined surgical and medical technique for auricular keloids
Jorge Román-Sainz, Belén Romero-Jiménez, Fernando Gruber-Velasco, Nicolás Silvestre-Torner, Adrián Imbernón-Moya
doi : 10.1111/dth.15372
New-onset lichen planus arising after COVID-19 vaccination
Orlando Zagaria, Alessia Villani, Angelo Ruggiero, Luca Potestio, Gabriella Fabbrocini, Lucia Gallo
doi : 10.1111/dth.15374
Erythrodermic psoriasis eruption associated with SARS-CoV-2 vaccination
Anna M. Nia, Madeline M. Silva, Jordan Spaude, Julian D. Gonzalez-Fraga
doi : 10.1111/dth.15380
New onset of pemphigus foliaceus following BNT162b2 vaccine
Şebnem Yıldırıcı, Savaş Yaylı, Cüyan Demirkesen, Seçil Vural
doi : 10.1111/dth.15381
Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient
Matteo Megna, Luisa Abategiovanni, Alberto Annunziata, Ginevra Torta, Tiziana Peduto, Gabriella Fabbrocini, Wanda Lauro
doi : 10.1111/dth.15382
Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report
Teresa Battista, Gianluca Guerrasio, Gaia De Fata Salvatores, Tiziana Peduto, Gabriella Fabbrocini, Adriana Di Guida
doi : 10.1111/dth.15383
Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma
Cristina Garcia-Melendo, Caridad E. Morales-Munera, Joan Dalmau, Xavier Cubiró, Cristina López-Sánchez, Anna Mozos, Oriol Yélamos
doi : 10.1111/dth.15388
Lichen Ruber Planus occurring after SARS-CoV-2 vaccination
Corrado Zengarini, Bianca Maria Piraccini, Michelangelo La Placa
doi : 10.1111/dth.15389
Pulsed cyclophosphamide sans pulse steroids in recalcitrant pemphigus: An effective, economical but underutilized modality
Snigdha Saxena, Ananta Khurana, Kabir Sardana
doi : 10.1111/dth.15392
Leg paralysis after photodynamic therapy for lymphomatoid papulosis: A case report
Lucia Genco, Teresa Battista, Matteo Noto, Mario De Lucia, Eleonora Cinelli, Massimiliano Scalvenzi, Gabriella Fabbrocini, Matteo Megna
doi : 10.1111/dth.15394
The staged forearm and leg interpolation flap in the treatment of cutaneous squamous cell carcinoma: A retrospective case series
Xue-Yan Chen, Li-En Tao, Bing-Xi Yan, Xiao-Yong Man
doi : 10.1111/dth.15398
De novo pustular psoriasis associated with dupilumab therapy in a young male with the diagnosis of atopic dermatitis
Pinar Incel Uysal, Omer Gunhan
doi : 10.1111/dth.15399
Certolizumab pegol as an alternative treatment in patients with coexisting hidradenitis suppurativa and other inflammatory immune-mediated diseases: Report of two cases
Francisco Javier Melgosa Ramos, Ramón GarcÃa Ruiz, Almudena Mateu Puchades
doi : 10.1111/dth.15401
Paradoxical Pandora's box of pigmentary side effects by imatinib mesylate in case of chronic myeloid leukemia
Snehal S. Pardeshi, Preeti Havanur, Vidya Kharkar, Sunanda Mahajan, Uday Khopkar
doi : 10.1111/dth.15402
A case of Melkersson–Rosenthal syndrome successfully treated with hydroxychloroquine
Stefano Caccavale, Paola Vitiello, Vittorio Tancredi, Antonello Sica, Andrea Ronchi, Renato Franco, Stefano Badolato, Giuseppe Argenziano
doi : 10.1111/dth.15409
Covid-19 vaccine associated erythema nodosum: Factors to consider
Katerina Damevska, Viktor Simeonovski
doi : 10.1111/dth.15410
A case of herpes zoster ophthalmicus after third dose of Comirnaty (BNT162b2 mRNA) vaccine
Fabrizio Martora, Gabriella Fabbrocini, Vincenzo Picone
doi : 10.1111/dth.15411
Four cases of hemorrhagic herpes zoster associated with dabigatran therapy
Stefano Veraldi, Andrea E. Beretta, Cristina Beatrice Spigariolo
doi : 10.1111/dth.15413
Injection site reaction with subcutaneous methotrexate
Carlota González-Moure, Olalla Figueroa-Silva, Olaya Ã�lvarez-GarcÃa, Pedro Gil-Pallares, Sandra Peña-López, Teresa Usero-Bárcena, Fernando Campo-Cerecedo, Tomás Ramón Vázquez-RodrÃguez, Benigno Monteagudo-Sánchez
doi : 10.1111/dth.15414
Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis
Cosimo Di Raimondo, Ludovico Rao, Flavia Lozzi, Paolo Lombardo, Dionisio Silvaggio, Laura Vellucci, Lorenzo Tofani, Elena Campione, Luca Bianchi
doi : 10.1111/dth.15421
Lichen planus and vitiligo occurring after ChAdOx1 nCoV-19 vaccination against SARS-CoV-2
Shirley Braga Lima Gamonal, Aloisio Carlos Couri Gamonal, Nathália Couri Vieira Marques, Caio Lima Adário
doi : 10.1111/dth.15422
Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?
Matteo Megna, Luca Potestio, Nicola Di Caprio, Andrea Tajani, Gabriella Fabbrocini, Alberto Annunziata
doi : 10.1111/dth.15423
Successful treatment with crisaborole for facial lesions refractory to adalimumab in a man with psoriasis: A case report
Yiyuan Liu, Wei Li
doi : 10.1111/dth.15424
Diffuse alopecia areata induced by brentuximab vedotin therapy for advanced stage mycosis fungoides
Elena Canal-Garcia, Francesc Alamon-Reig, Andrea Combalia
doi : 10.1111/dth.15427
A case of Grover disease treated with Dupilumab: Just serendipity or a future perspective?
Francesca Barei, Sara Torretta, Nicole Morini, Silvia Ferrucci
doi : 10.1111/dth.15429
Professor Sławomir Majewski (1956–2022): An innovative academic giant
Robert A. Schwartz
doi : 10.1111/dth.15473
